Finally, comparing the survival of pancreatic adenocarcinoma patients with high (n = 44) versus low (n = 46) EFR3A mRNA levels from the TGCA database revealed a 29% reduction in overall median survival of the former (Supplementary Fig. 2e). Here, EFR3A is linked to pancreatic adenocarcinoma.